Search form


Press Releases

Axcan announces conference call on statistical approach for Phase III trials of ITAX

Feb 13, 2006 - 11:59 ET


Attention Business/Financial/Health Editors:

TSX SYMBOL (Toronto Stock Exchange): AXP

Axcan Pharma Inc. (NASDAQ:AXCA - TSX: AXP) announced today
that based on clear interest in obtaining
additional insight into the statistical methods that will be used to analyze
the results of its ITAX (Itopride) Phase III pivotal trials, the Company will
host a conference call on February 13, 2006 at 9:00 A.M. E.S.T.

The telephone numbers to access the conference call are (800) 796-7558
(Canada and United States) or (416) 644-3425 (international). A replay of the
call will be available until February 20, 2006. The telephone number to access
the replay of the call is (416) 640-1917 code: 21177134. Interested parties
may also access the conference call by web cast at The web cast
will be archived for 90 days.

The main topic of the conference call will be the statistical approach
that will be used to analyze the results of the Itopride Phase III pivotal

Axcan also wishes to reiterate the Company is on track to meet the
timeline that was announced on August 11, 2005 with the planned filing of a
New Drug Application for Itopride with the U.S. Food and Drug Administration
in the summer of 2006. As also announced in August of 2005, overall results of
the International Phase III clinical trial will be disclosed during the first
half of calendar 2006, followed shortly by the North American Phase III trial.
Details from the International study will be submitted to a major
gastroenterology and scientific conference following the announcement of the
International study results. A similar approach will be taken for the North
American Study.


Axcan is a leading specialty pharmaceutical company specialized in the
field of gastroenterology. Axcan markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to Cystic Fibrosis.
Axcan's products are marketed by its own sales force in North America and the
European Union. Its common shares are listed on the Toronto Stock Exchange
under the symbol "AXP" and on the NASDAQ National Market under the symbol

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

This release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. To the extent any
statements made in this release contain information that is not historical,
these statements are essentially forward-looking and are often identified by
words such as "anticipate," "expect," "estimate," "intend," "project," "plan"
and "believe." Forward-looking statements are subject to risks and
uncertainties, including the difficulty of predicting FDA and other regulatory
approvals, acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials, the
regulatory environment, fluctuations in operating results, the protection of
our intellectual property and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission and the Canadian
Securities Regulators, including under the Canadian Multijurisdictional
Disclosure System.

The name ITAX appearing in this press release is a trademark of Axcan Pharma Inc. and its subsidiaries.

For further information: Isabelle Adjahi, Director, Investor Relations,
Axcan Pharma Inc., (450) 467-2600 ext. 2000,; Source: Axcan
Pharma inc.